open access

Vol 13, No 2 (2010)
Original articles
Published online: 2011-05-20
Submitted: 2012-01-23
Get Citation

Biokinetics of 131I after endogenous and exogenous stimulation of TSH in patients with DTC

Monika Buziak-Bereza, Monika Tomaszuk, Dorota Pach, Anna Sowa-Staszczak, Agata Bałdys-Waligórska, Bogusław Głowa, Maciej Kołodziej, Alicja B. Hubalewska-Dydejczyk
Nucl. Med. Rev 2010;13(2):55-58.

open access

Vol 13, No 2 (2010)
Original articles
Published online: 2011-05-20
Submitted: 2012-01-23

Abstract

BACKGROUND: The effective radioiodine treatment of patients with DTC is possible only after raising the TSH value over 30 μUI/ml. This effect might be obtained by either endogenous or exogenous stimulation. The aim of this study was to evaluate differences in 131I biokinetics of selected regions of interest (ROIs) in cases of endogenous and exogenous stimulation.
MATERIAL AND METHODS: Two groups of 50 patients were enrolled in the study. All patients were treated with 3.7 GBq of 131I; the first group after thyroid hormone withdrawal (THW), the second group after rhTSH administration (rhTSH). On the basis of post-treatment images, the uptake ratios over selected ROIs (thyroid remnants, mediastinum, liver, stomach, abdomen, and whole-body) were compared between groups.
RESULTS: In the case of uptake over the whole-body and the liver, statistically significant higher values were received for the THW group. For the remaining regions, the differences between groups were statistically insignificant, but uptake ratios in the rhTSH group were generally numerically lower compared to the THW group.
CONCLUSIONS: The revealed difference in radioiodine biokinetics after thyroid hormone withdrawal or administration of recombinant human TSH may influence many important aspects of patients with DTC treatment, such as the choice of proper therapeutic scheme, the cost of therapy, and the dose assessment.
Nuclear Med Rev 2010; 13, 2: 55–58

Abstract

BACKGROUND: The effective radioiodine treatment of patients with DTC is possible only after raising the TSH value over 30 μUI/ml. This effect might be obtained by either endogenous or exogenous stimulation. The aim of this study was to evaluate differences in 131I biokinetics of selected regions of interest (ROIs) in cases of endogenous and exogenous stimulation.
MATERIAL AND METHODS: Two groups of 50 patients were enrolled in the study. All patients were treated with 3.7 GBq of 131I; the first group after thyroid hormone withdrawal (THW), the second group after rhTSH administration (rhTSH). On the basis of post-treatment images, the uptake ratios over selected ROIs (thyroid remnants, mediastinum, liver, stomach, abdomen, and whole-body) were compared between groups.
RESULTS: In the case of uptake over the whole-body and the liver, statistically significant higher values were received for the THW group. For the remaining regions, the differences between groups were statistically insignificant, but uptake ratios in the rhTSH group were generally numerically lower compared to the THW group.
CONCLUSIONS: The revealed difference in radioiodine biokinetics after thyroid hormone withdrawal or administration of recombinant human TSH may influence many important aspects of patients with DTC treatment, such as the choice of proper therapeutic scheme, the cost of therapy, and the dose assessment.
Nuclear Med Rev 2010; 13, 2: 55–58
Get Citation

Keywords

endogenous stimulation; exogenous stimulation; thyroid hormone withdrawal; recombinant human TSH; radioiodine treatment; DTC

About this article
Title

Biokinetics of 131I after endogenous and exogenous stimulation of TSH in patients with DTC

Journal

Nuclear Medicine Review

Issue

Vol 13, No 2 (2010)

Pages

55-58

Published online

2011-05-20

Bibliographic record

Nucl. Med. Rev 2010;13(2):55-58.

Keywords

endogenous stimulation
exogenous stimulation
thyroid hormone withdrawal
recombinant human TSH
radioiodine treatment
DTC

Authors

Monika Buziak-Bereza
Monika Tomaszuk
Dorota Pach
Anna Sowa-Staszczak
Agata Bałdys-Waligórska
Bogusław Głowa
Maciej Kołodziej
Alicja B. Hubalewska-Dydejczyk

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl